220 related articles for article (PubMed ID: 33891473)
1. Building External Control Arms From Patient-Level Electronic Health Record Data to Replicate the Randomized IMblaze370 Control Arm in Metastatic Colorectal Cancer.
Schröder C; Lawrance M; Li C; Lenain C; Mhatre SK; Fakih M; Reyes-Rivera I; Bretscher MT
JCO Clin Cancer Inform; 2021 Apr; 5():450-458. PubMed ID: 33891473
[TBL] [Abstract][Full Text] [Related]
2. Pertuzumab Plus Trastuzumab for Treatment-Refractory
Narita Y; Yoshimoto T; Namai T; Asakawa T; Kawakami S; Gower-Page C; Reyes-Rivera I; Patel A; Nakamura Y
JCO Clin Cancer Inform; 2022 May; 6():e2200022. PubMed ID: 35649212
[TBL] [Abstract][Full Text] [Related]
3. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.
Eng C; Kim TW; Bendell J; Argilés G; Tebbutt NC; Di Bartolomeo M; Falcone A; Fakih M; Kozloff M; Segal NH; Sobrero A; Yan Y; Chang I; Uyei A; Roberts L; Ciardiello F;
Lancet Oncol; 2019 Jun; 20(6):849-861. PubMed ID: 31003911
[TBL] [Abstract][Full Text] [Related]
4. Emulating Control Arms for Cancer Clinical Trials Using External Cohorts Created From Electronic Health Record-Derived Real-World Data.
Tan K; Bryan J; Segal B; Bellomo L; Nussbaum N; Tucker M; Torres AZ; Bennette C; Capra W; Curtis M; Miksad RA
Clin Pharmacol Ther; 2022 Jan; 111(1):168-178. PubMed ID: 34197637
[TBL] [Abstract][Full Text] [Related]
5. Using Electronic Health Records to Derive Control Arms for Early Phase Single-Arm Lung Cancer Trials: Proof-of-Concept in Randomized Controlled Trials.
Carrigan G; Whipple S; Capra WB; Taylor MD; Brown JS; Lu M; Arnieri B; Copping R; Rothman KJ
Clin Pharmacol Ther; 2020 Feb; 107(2):369-377. PubMed ID: 31350853
[TBL] [Abstract][Full Text] [Related]
6. Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer.
Li C; Ferro A; Mhatre SK; Lu D; Lawrance M; Li X; Li S; Allen S; Desai J; Fakih M; Cecchini M; Pedersen KS; Kim TY; Reyes-Rivera I; Segal NH; Lenain C
Commun Med (Lond); 2022; 2():90. PubMed ID: 35856081
[TBL] [Abstract][Full Text] [Related]
7. Time to treatment initiation and its impact on real-world survival in metastatic colorectal cancer and pancreatic cancer.
Gbolahan O; Hashemi-Sadraei N; Yash S; Williams G; Ramachandran R; Kim YI; Paluri R; Outlaw D; El-Rayes B; Nabell L
Cancer Med; 2023 Feb; 12(3):3488-3498. PubMed ID: 35979540
[TBL] [Abstract][Full Text] [Related]
8. RAS Amplification as a Negative Predictor of Benefit from Anti-EGFR-Containing Therapy Regimens in Metastatic Colorectal Cancer.
Schrock AB; Lee JK; Sandhu J; Madison R; Cho-Phan C; Snider JW; Castellanos E; Venstrom JM; Fakih M
Oncologist; 2021 Jun; 26(6):469-475. PubMed ID: 33465286
[TBL] [Abstract][Full Text] [Related]
9. Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced/Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-Based External Control Arm.
Goulden S; Shen Q; Coleman RL; Mathews C; Hunger M; Pahwa A; Schade R
J Health Econ Outcomes Res; 2023; 10(2):53-61. PubMed ID: 37701519
[No Abstract] [Full Text] [Related]
10. Efficacy and Safety of Proposed Bevacizumab Biosimilar BE1040V in Patients With Metastatic Colorectal Cancer: A Phase III, Randomized, Double-blind, Noninferiority Clinical Trial.
Rezvani H; Mortazavizadeh SM; Allahyari A; Nekuee A; Najafi SN; Vahidfar M; Ghadyani M; Khosravi A; Qarib S; Sadeghi A; Esfandbod M; Rajaeinejad M; Rezvani A; Hajiqolami A; Payandeh M; Shazad B; Anjidani N; Meskinimood S; Alikhasi A; Karbalaeian M; Salari S
Clin Ther; 2020 May; 42(5):848-859. PubMed ID: 32334845
[TBL] [Abstract][Full Text] [Related]
11. Upfront primary tumor resection versus upfront systemic therapy for metastatic colorectal cancer: a systematic review and meta-analysis.
Lo SJ; Huang SH; Lai IL; Chern YJ; Hsu YJ; Liao CK; Cheng CC; Tsai WS; Hsieh PS; You JF
Int J Colorectal Dis; 2023 Jul; 38(1):186. PubMed ID: 37405554
[TBL] [Abstract][Full Text] [Related]
12. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y
Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015
[TBL] [Abstract][Full Text] [Related]
13. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.
Arnold D; Lueza B; Douillard JY; Peeters M; Lenz HJ; Venook A; Heinemann V; Van Cutsem E; Pignon JP; Tabernero J; Cervantes A; Ciardiello F
Ann Oncol; 2017 Aug; 28(8):1713-1729. PubMed ID: 28407110
[TBL] [Abstract][Full Text] [Related]
15. Capecitabine plus temozolomide (CapTem): An alternative regimen to regorafenib as third-line setting in metastatic colorectal cancer?
Ergun Y; Bal O; Dogan M; Uncu D
J BUON; 2019; 24(6):2435-2441. PubMed ID: 31983117
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC).
Schimanski CC; Kasper S; Hegewisch-Becker S; Schröder J; Overkamp F; Kullmann F; Bechstein WO; Vöhringer M; Öllinger R; Lordick F; Heinemann V; Geißler M; Schulz-Abelius A; Bernhard H; Schön MR; Greil R; Galle P; Lang H; Schmidtmann I; Moehler M
Oncoimmunology; 2020 Aug; 9(1):1806680. PubMed ID: 32923171
[TBL] [Abstract][Full Text] [Related]
17. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
[TBL] [Abstract][Full Text] [Related]
18. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
[TBL] [Abstract][Full Text] [Related]
19. Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression.
Obermannová R; Van Cutsem E; Yoshino T; Bodoky G; Prausová J; Garcia-Carbonero R; Ciuleanu T; Garcia Alfonso P; Portnoy D; Cohn A; Yamazaki K; Clingan P; Lonardi S; Kim TW; Yang L; Nasroulah F; Tabernero J
Ann Oncol; 2016 Nov; 27(11):2082-2090. PubMed ID: 27573561
[TBL] [Abstract][Full Text] [Related]
20. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY
Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]